Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CUV.AU
- Price
- 10.95
- Stock movement down
- -0.30 (-2.67%)
- Company name
- Clinuvel Pharmaceuticals Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 548.16M
- Ent value
- 392.41M
- Price/Sales
- 3.40
- Price/Book
- 2.70
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- 8.18%
- Trailing P/E
- 8.50
- Forward P/E
- 15.42
- PEG
- -
- EPS growth
- 13.80%
- 1 year return
- -29.85%
- 3 year return
- -15.60%
- 5 year return
- -11.91%
- 10 year return
- 14.37%
Last updated: 2025-04-04
DIVIDENDS
CUV.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 8.50 |
| Price to OCF | 9.00 |
| Price to FCF | 10.08 |
| Price to EBITDA | 6.05 |
| EV to EBITDA | 4.33 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.40 |
| Price to Book | 2.70 |
| EV to Sales | 2.44 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.06M |
| EPS (TTM) | 1.28 |
| FCF per share (TTM) | 1.08 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 161.08M |
| Gross profit (TTM) | 122.85M |
| Operating income (TTM) | 86.42M |
| Net income (TTM) | 64.46M |
| EPS (TTM) | 1.28 |
| EPS (1y forward) | 0.71 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 76.27% |
| Operating margin (TTM) | 53.65% |
| Profit margin (TTM) | 40.02% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 183.87M |
| Net receivables | 26.24M |
| Total current assets | 222.06M |
| Goodwill | 0.00 |
| Intangible assets | 185.03K |
| Property, plant and equipment | 10.66M |
| Total assets | 231.12M |
| Accounts payable | 2.35M |
| Short/Current long term debt | 879.78K |
| Total current liabilities | 25.21M |
| Total liabilities | 28.11M |
| Shareholder's equity | 203.01M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 60.89M |
| Capital expenditures (TTM) | 6.52M |
| Free cash flow (TTM) | 54.36M |
| Dividends paid (TTM) | 4.45M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 31.75% |
| Return on Assets | 27.89% |
| Return on Invested Capital | 31.70% |
| Cash Return on Invested Capital | 26.73% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.01 |
| Daily high | 11.14 |
| Daily low | 10.83 |
| Daily Volume | 178K |
| All-time high | 45.00 |
| 1y analyst estimate | 28.29 |
| Beta | 0.85 |
| EPS (TTM) | 1.28 |
| Dividend per share | - |
| Ex-div date | 5 Sep 2024 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CUV.AU | S&P500 | |
| Current price drop from All-time high | -75.67% | -12.44% |
| Highest price drop | -92.52% | -56.47% |
| Date of highest drop | 30 Dec 2013 | 9 Mar 2009 |
| Avg drop from high | -55.73% | -11.07% |
| Avg time to new high | 75 days | 12 days |
| Max time to new high | 2800 days | 1805 days |
COMPANY DETAILS
Marketcap
548.16M
Marketcap category
Small-cap
Description
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found